Jennifer Dulaney, DO
Family Medicine · Norton Shores, MINPI 1922445022
Payments from drug & device makers
Across 65 payments — averaging $14.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$197
- Pfizer$185
- Novo Nordisk$123
- Amgen$88
- Boehringer Ingelheim$60
- AstraZeneca$51
- plus $254 from 13 others
What the payments were for
- Food & beverage$93998%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 5 | $197 |
| Pfizer | 22 | $185 |
| Novo Nordisk | 7 | $123 |
| Amgen | 6 | $88 |
| Boehringer Ingelheim | 4 | $60 |
| AstraZeneca | 4 | $51 |
| Novartis | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $20 |
| Si-bone, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Tris Pharma Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$958 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $143,611 |
| JardianceEmpagliflozin | 67 | $82,935 |
| OzempicSemaglutide | 66 | $80,982 |
| TrulicityDulaglutide | 59 | $80,126 |
| MounjaroTirzepatide | 66 | $66,919 |
| FarxigaDapagliflozin Propanediol | 52 | $52,686 |
| XareltoRivaroxaban | 38 | $43,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $25,685 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $21,073 |
| Atorvastatin Calcium | 735 | $12,087 |
| LyricaPregabalin | 11 | $9,539 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $9,083 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,986 |
| Varenicline Tartrate | 26 | $8,392 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $8,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $185 | $153,150144 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $14 | $147,045125 claims |
| Boehringer IngelheimJardiance | $60 | $82,93567 claims |
| Novo NordiskOzempic | $123 | $80,98266 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $14 | $63,11494 claims |
| AstraZenecaFarxiga, Symbicort | $51 | $56,78463 claims |
| Johnson & JohnsonXarelto, Invokana | $16 | $49,72749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Norton Shores
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.